EXHIBIT
5.1
March 3,
2010
Nile
Therapeutics, Inc.
4 West
4th Street, Suite 400
San
Mateo, CA
Ladies
and Gentlemen:
This
opinion is being furnished to you in connection with the Registration Statement
on Form S-3 (the “Registration Statement”), including the prospectus that is
part of the Registration Statement (the “Prospectus”), filed by Nile
Therapeutics, Inc., a Delaware corporation (the “Company”), with the Securities
and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended
(the “Securities Act”) on or about the date hereof. The Prospectus provides that
it will be supplemented in the future by one or more prospectus supplements
(each, a “Prospectus Supplement”). The Prospectus, as supplemented by the
various Prospectus Supplements, will provide for the issuance and sale by the
Company from time to time of (i) shares of common stock, par value $0.001 per
share (the “Common Stock”); (ii) shares of preferred stock, par value $0.001 per
share (the “Preferred Stock”); (iii) one or more series of the debt securities
of the Company, which may be either senior securities or subordinated securities
and which may be convertible into or exchangeable for shares of Common Stock or
Preferred Stock (the “Debt Securities”); or (iv) warrants to purchase shares of
Common Stock, shares of Preferred Stock and/or Debt Securities (the
“Warrants”).
The
Common Stock, the Preferred Stock, the Debt Securities and the Warrants are
collectively referred to herein as the “Securities.” The Securities are being
registered for offering and sale from time to time pursuant to Rule 415 under
the Securities Act. The maximum aggregate public offering price of the
Securities being registered is $25,000,000.
The Debt
Securities will be issued pursuant to one or more indentures in the form filed
as an exhibit to the Registration Statement, as amended or supplemented from
time to time (each, an “Indenture”), between the Company, as obligor, and a
trustee chosen by the Company and qualified to act as such under the Trust
Indenture Act of 1939, as amended (the “Trustee”).
We have
examined and relied upon the information set forth in the Registration Statement
and such other records, agreements, certificates and documents, and have made
legal and factual inquiries, as we have deemed necessary as a basis for the
opinions expressed herein. As to questions of fact not independently verified by
us, we have relied upon certificates of public officials and officers of the
Company.
The
opinions expressed herein are limited to matters governed by the Delaware
General Corporation Law, including the applicable provisions of the Delaware
constitution and the reported cases interpreting those laws.
Based
upon the foregoing and subject to the additional qualifications set forth below,
we are of the opinion that:
Nile
Therapeutics, Inc.
March
3, 2010
Page
2
|
|
1. When
the issuance and the terms of the sale of the shares of Common Stock have been
duly authorized by the board of directors of the Company in conformity with its
certificate of incorporation, and such shares have been issued and delivered
against payment of the purchase price therefor in an amount in excess of the par
value thereof, in accordance with the applicable definitive purchase,
underwriting or similar agreement, and as contemplated by the Registration
Statement, the Prospectus and the related Prospectus Supplement, and, if issued
upon the conversion, exchange or exercise of Debt Securities or Warrants, when
such shares have been duly issued and delivered as contemplated by the terms of
the applicable Indenture or Warrant, the shares of Common Stock will be validly
issued, fully paid and nonassessable.
2. When
the issuance and the terms of the sale of the shares of Preferred Stock have
been duly authorized by the board of directors of the Company in conformity with
its certificate of incorporation; an appropriate certificate of designation
relating to a series of the Preferred Stock to be sold under the Registration
Statement has been duly authorized and adopted and filed with the Secretary of
State of Delaware; the terms of issuance and sale of shares of such series of
Preferred Stock have been duly established in conformity with the Company’s
certificate of incorporation and by-laws so as to not violate any applicable law
or result in a default under, or breach of, any agreement or instrument binding
upon the Company and so as to comply with any requirement or restriction imposed
by any court or governmental or regulatory body having jurisdiction over the
Company or any of its property; and such shares have been issued and delivered
against payment of the purchase price therefor in an amount in excess of the par
value thereof, in accordance with the applicable definitive purchase,
underwriting or similar agreement, and as contemplated by the Registration
Statement, the Prospectus and the related Prospectus Supplement, and, if issued
upon the conversion, exchange or exercise of any Debt Securities or Warrants,
when such shares have been duly issued and delivered as contemplated by the
terms of the applicable Indenture or Warrant, the shares of Preferred Stock will
be validly issued, fully paid and nonassessable.
3. When
the issuance and the terms of the sale of the Debt Securities have been duly
authorized by the board of directors of the Company and duly established in
conformity with the applicable Indenture so as not to violate any applicable law
or result in a default under, or breach of, any agreement or instrument binding
upon the Company and so as to comply with any requirement or restriction imposed
by any court or governmental or regulatory body having jurisdiction over the
Company or any of its property, and the Debt Securities have been duly executed,
authenticated, issued, delivered and sold in accordance with the applicable
definitive purchase, underwriting or similar agreement, as contemplated by the
Registration Statement, the Prospectus and the related Prospectus Supplement,
and in the manner provided for in the applicable Indenture against payment of
the purchase price therefor, the Debt Securities will constitute valid and
binding obligations of the Company enforceable against the Company in accordance
with their respective terms.
4. When
the issuance and the terms of the sale of the Warrants have been duly authorized
by the board of directors of the Company; the terms of the Warrants and of their
issuance and sale have been duly established so as to not violate any applicable
law or result in a default under, or breach of, any agreement or instrument
binding upon the Company and so as to comply with any requirement or restriction
imposed by any court or governmental or regulatory body having jurisdiction over
the Company or any of its property; and the Warrants have been duly executed and
issued and sold in accordance with the applicable definitive purchase,
underwriting or similar agreement, as contemplated by the Registration
Statement, the Prospectus and the related Prospectus Supplement, the Warrants
will constitute valid and binding obligations of the Company enforceable against
the Company in accordance with their terms.
Nile
Therapeutics, Inc.
March
3, 2010
Page
3
|
|
In
rendering the opinions set forth above, we have assumed that: (i) the
Registration Statement will have become effective under the Securities Act, a
Prospectus Supplement will have been prepared and filed with the SEC describing
the Securities offered thereby and such Securities will have been issued and
sold in accordance with the terms of such Prospectus Supplement; (ii) a
definitive purchase, underwriting or similar agreement with respect to such
Securities (if applicable) will have been duly authorized, executed and
delivered by the Company and the other parties thereto; (iii) the Securities
will be duly authorized by all necessary corporate action by the Company and any
Indenture, any applicable supplemental indenture thereto and any other agreement
pursuant to which such Securities may be issued will be duly authorized,
executed and delivered by the Company and the other parties thereto; (iv) the
Company is, and will remain, duly organized, validly existing and in good
standing under applicable state law; and (v) the Company will have reserved a
sufficient number of shares of its duly authorized, but unissued, Common Stock
and Preferred Stock as is necessary to provide for the issuance of the shares of
Common Stock and Preferred Stock pursuant to the Registration
Statement.
The
opinions set forth above are subject to the following exceptions, limitations
and qualifications: (i) the effect of bankruptcy, insolvency, reorganization,
fraudulent conveyance, moratorium or other similar laws now or hereafter in
effect relating to or affecting the rights and remedies of creditors; (ii) the
effect of general principles of equity, including without limitation, concepts
of materiality, reasonableness, good faith and fair dealing and the possible
unavailability of specific performance or injunctive relief, regardless of
whether enforcement is considered in a proceeding in equity or at law, and the
discretion of the court before which any proceeding therefor may be brought; and
(iii) the unenforceability under certain circumstances under law or court
decisions of provision providing for the indemnification of, or contribution to,
a party with respect to a liability where such indemnification or contribution
is contrary to public policy. We express no opinion (i) concerning the
enforceability of any waiver of rights or defenses with respect to stay,
extension or usury laws or (ii) with respect to whether acceleration of Debt
Securities may affect the collectibility of any portion of the stated principal
amount thereof which might be determined to constitute unearned interest
thereon. Our opinions expressed herein are also subject to the qualification
that no term or provision shall be included in any Indenture, any Warrant or any
other agreement or instrument pursuant to which any of the Securities are to be
issued that would affect the validity of such opinions.
We hereby
consent to the filing of this letter as an exhibit to the Registration Statement
and to the reference to this firm under the caption “Legal Matters” in the
Prospectus included therein. This opinion may be used only in connection with
the offer and sale of the Securities while the Registration Statement is
effective. The opinions expressed herein are only as of the date hereof, and we
disclaim any undertaking to advise you of any subsequent changes in the facts
stated or assumed herein or of any subsequent changes in applicable
law.
|
Very
truly yours,
|
|
|
|
/s/
Fredrikson & Byron, P.A.
|